Greenwich LifeSciences, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; unaudited. Greenwich is a clinical-stage biopharmaceutical company developing GLSI-100 (GP2 plus GM-CSF), an immunotherapy intended to prevent breast cancer recurrence. Its Phase III Flamingo-01 trial is expanding into Europe, with plans to open up to 150 sites. The company reported no revenue.
Financial results and liquidity
- Revenue: $0, unchanged from Q1 2023.
- Operating expenses: $2.54 million, up 13% year over year. Research and development was $2.19 million, up 20%, primarily due to increased clinical expenses; general and administrative expense was $343,000, down 17%.
- Net loss: $2.47 million, compared with $2.12 million in Q1 2023; loss per share was $0.19 versus $0.17.
- Cash flow: Operating cash used was $1.78 million, compared with $1.56 million a year earlier. Cash declined by $1.48 million during the quarter to $5.51 million.
- Balance sheet: Total assets were $5.51 million and total liabilities were $390,000 at quarter-end. Liabilities included accounts payable and accrued interest; the filing does not disclose funded debt. Accrued interest owed to HJF was $221,000.
- Equity financing: The ATM program generated $299,000 in net proceeds from 27,117 shares during Q1. After quarter-end through May 8, the company sold another 4,713 shares for $72,000 net.
Changes, outlook and risks
- Year-over-year net loss increased by about 16%, reflecting higher research and development spending; G&A expense decreased.
- Management expects significant expenses and operating losses to continue as it develops GLSI-100 and conducts clinical trials. No specific financial or clinical guidance was provided.
- The company has incurred losses since inception and negative operating cash flows. Management disclosed substantial doubt about its ability to continue as a going concern and said continued operations depend on obtaining additional capital. There is no assurance financing will be available.
- Key business risks include clinical-trial execution and results, regulatory approval, financing needs, and reliance on third-party manufacturers. The company said there were no material changes to the risk factors in its 2023 Form 10-K.
- Disclosure controls were not effective at March 31, 2024 because of material weaknesses involving segregation of duties and insufficient written accounting, IT, and financial-reporting procedures. Management is developing a remediation plan.
- The company reported no material legal proceedings, material contractual obligations beyond employment and shareholder agreements and the HJF license, or off-balance-sheet arrangements.
Important facts for investors to verify
- Available cash, projected cash needs, and the timing and terms of any additional financing.
- Flamingo-01 enrollment, European site expansion, trial milestones, and any updates to clinical timelines or results.
- Progress in remediating the disclosed internal-control material weaknesses.
- Future ATM issuance and resulting share dilution; also note the director, officer, and certain shareholder lock-up was extended to June 30, 2025.
- Terms and potential costs under the HJF license, including maintenance fees, milestones, royalties, patent expenses, and accrued interest.